IL15 and neoplasm: To assess potential alterations in CD215+ myeloid cells after IL-15 treatment, we FACS-purified CD45+ CD11b+ Gr-1+ CD215+ and CD45+ CD11b+ Gr-1+ CD215− cells from the tumor tissue of tumor-bearing mice and performed transcriptome profiling of these populations from two independent mice with or without IL-15 treatment using RNA-Seq.